News

The companies struck a collaboration deal for the development and commercialization of ADXS-NEO. Under the deal, Amgen will pay Advaxis $40m upfront along with a $25m equity investment.

The US Food and Drug Administration granted the designation to LEE011 in combination with letrozole for treating hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced

The antibody, targeting refractory leptomeningeal tumor neuroblastoma and diffuse intrinsic pontine glioma, is a potential breakthrough treatment for pediatric patients. Following transfer of Y-mAbs' lead cell line to

Bamboo Therapeutics is engaged in the development of gene therapies for rare and devastating central nervous system and neuromuscular diseases In the first quarter of this year, Pfizer

NEO-PV-01 is a personalized vaccine designed specifically for each patient based on the neoantigen mutations unique to that patient’s tumor DNA. The IND enables Neon Therapeutics to initiate

The CRL did not cite any concerns with the clinical safety and efficacy data for RI-002 submitted by ADMA in the BLA, nor has the FDA requested any

The gene and cell therapy group recently established and commissioned a second specialist bioprocessing clean room suite at Harrow House and at its new laboratories at Windrush Court

Under the terms of the agreement, Profil Institute will provide clinical research and development services, from IND readiness through the completion of early phase development, including regulatory and

The approval of Adlyxin reaffirms our continued commitment to addressing the challenges faced by people living with diabetes when trying to reach and maintain their individual blood glucose